Association between 5-α reductase inhibition and risk of hip fracture

JAMA

Volumn 300, Issue 14, 2008, Pages 1660-1664

  Jacobsen, Steven J ^a   Cheetham, T Craig ^a   Haque, Reina ^a   Shi, Jiaxiao M ^a   Loo, Ronald K ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; FINASTERIDE; PHENOXYBENZAMINE; PHENTOLAMINE; PRAZOSIN; STEROID 5ALPHA REDUCTASE; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; HEALTH CARE ORGANIZATION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK FACTOR;

EID: 53749108051     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.14.1660     Document Type: Article

References (22)

1. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med. 1995;155(5):477-481.
2. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003), chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170(2, pt 1):530-547.
3. Wei JT, Calhoun E, Jacobsen SJ. Urologic Diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256-1261.
4. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4, pt 1):1399-1403.
5. Castro-Magana M, Angulo M, Fuentes B, et al. Effect of finasteride on human testicular steroidogenesis. J Androl. 1996;17(5):516-521.
6. Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J. Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab. 2006;91(8):3017-3023.
7. Khosla S, Melton LJ III, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab. 2002;87(4):1443-1450.
8. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86(8):3555-3561.
9. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503-510.
10. Matsumoto AM, Tenover L, McClung M, et al. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002;167(5):2105-2108.
11. Tollin SR, Rosen HN, Zurowski K, et al. Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia - a Clinical Research Center study. J Clin Endocrinol Metab. 1996;81(3):1031-1034.
12. Issa S, Schnabel D, Feix M, et al. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1. J Clin Endocrinol Metab. 2002;87(12):5401-5407.
13. Somjen D, Katzburg S, Stern N, et al. 25 hydroxyvitamin D(3)-1alpha hydroxylase expression and activity in cultured human osteoblasts and their modulation by parathyroid hormone, estrogenic compounds and dihydrotestosterone. J Steroid Biochem Mol Biol. 2007;107(3-5):238-244.
14. Bergstralh EJ, Kosanke JL, Jacobsen SJ. Software for optimal matching in observational studies. Epidemiology. 1996;7(3):331-332.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
17. Colvard DS, Eriksen EF, Keeting PE, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A. 1989;86(3):854-857.
18. Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006;166(19):2124-2131.
19. Clayman RV. Long-term combined treatment with thiazide and potassium citrate in nephrolithiasis does not lead to hypokalemia or hypochloremic metabolic alkalosis. J Urol. 2005;173(4):1200.
20. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health. 1990;80(7):871-873.
21. Sandler RB, Cauley JA, Hom DL, Sashin D, Kriska AM. The effects of walking on the cross-sectional dimensions of the radius in postmenopausal women. Calcif Tissue Int. 1987;41(2):65-69.
22. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36(1):1-13.